Skip to main content
Clinical Trials/PACTR202205715278722
PACTR202205715278722RecruitingPhase 1

Phase I study to determine Safety and Pharmacokinetics of subcutaneous administration of potent and broadly neutralizing anti-HIV-1 monoclonal antibodies (bNAbs), given to HIV-1 exposed uninfected (HEU) neonates and infants.

South African Medical Research Council0 sites72 target enrollmentStarted: April 21, 2022Last updated:
Conditions

Trial Snapshot

Phase
Phase 1
Status
Recruiting
Sponsor
Enrollment
72

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
0 Day(s) to 1 Month(s) (—)
Sex
Female

Inclusion Criteria

  • Greater than or equal to 18 years of age
  • Documented HIV-1 infection
  • Breastfeeding at the time of consenting or willing to initiate breastfeeding in the immediate post partum period.
  • Able and willing to provide a signed informed consent form to participate in the study for herself and her infant.
  • Alive infant with a birth weight greater than or equal to 2.0 kg and lower than or equal to 4.0kg
  • Gestational age greater or equal to 36 weeks, assessed using birth Ballard Score (done up to 42 hours after birth)
  • Written consent of the one or both parents (according to South African regulation)

Exclusion Criteria

  • Prior participation in any HIV-1 vaccine trial
  • Receipt of any other active or passive HIV immunotherapy or investigational product concurrently
  • Documented or suspected serious medical illness with fetal compromise or immediate life-threatening condition (other than HIV-infection as judged by the examining clinician)
  • Most recent CD4 count (within a time frame of =6 months) under 350 cells/mm3
  • Mother not on ART
  • Unable or not willing to breastfeed
  • Active tubercolosis
  • COVID-19 diagnosis in the past month
  • Plan to relocate in 1 year
  • Mother does not have her own cell phone
  • Mother not able to provide three alternate contact phone numbers
  • HIV-infected on birth PCR
  • Receipt of or anticipated need for blood product, immunoglobulin or immunosuppressive therapy. This includes infants who require hepatitis B immunoglobulins (HBIG) but not infants who receive hepatitis B vaccine in the new-born period
  • Documented or suspected serious medical or immediate life-threatening condition
  • Infant in ICU or high care requiring supplemental oxygen at time of first bNAb dose
  • Known allergy to study drug or components
  • Multiple birth, i.e. twins, triplets, quadruplets, etc
  • Baseline laboratory results:
  • Haemoglobin level less than 12.0 g/dL
  • Platelet count less than 100,000 cells/mm3
  • Absolute neutrophil count: for infants less than 24 hours old, less than 4,000 cells/mm3; for infants greater than 24 hours old, less than 1,250 cells/mm3
  • Serum glutamic pyruvic transaminase (SGPT), alanine aminotransferase (ALT) greater than or equal to 1.25 times upper limit of age-adjusted normal.
  • Serum bilirubin at a level needing phototherapy

Investigators

Sponsor
South African Medical Research Council

Similar Trials